Abstract: In example embodiments, a radiation source uses Rydberg states to generate coherent THz radiation (e.g., in the range of 1-20 THz). The radiation source includes a pair of pump lasers (e.g., external-cavity diode lasers (ECDLs)) optically coupled (e.g., by a dichroic mirror and optical fiber) to a heated vapor cell (e.g., a vacuum chamber) holding an atomic species (e.g., rubidium (Rb)). The pump lasers optically pump the atomic species (e.g., Rb) to a predetermined Rydberg state (e.g., the nD5/2 state), which creates a population inversion between that state (e.g., the nD5/2 state) and a lower lying Rydberg state (e.g., the (n+1)P3/2 state). The emission between these two strongly dipole coupled Rydberg states generates coherent THz radiation.

Abstract: In example embodiments, a radiation source uses Rydberg states to generate coherent THz radiation (e.g., in the range of 1-20THz). The radiation source includes a pair of pump lasers (e.g., external-cavity diode lasers (ECDLs)) optically coupled (e.g., by a dichroic mirror and optical fiber) to a heated vapor cell (e.g., a vacuum chamber) holding an atomic species (e.g., rubidium (Rb)). The pump lasers optically pump the atomic species (e.g., Rb) to a predetermined Rydberg state (e.g., the nD5/2 state), which creates a population inversion between that state (e.g., the nD5/2 state) and a lower lying Rydberg state (e.g., the (n+1)P3/2 state). The emission between these two strongly dipole coupled Rydberg states generates coherent THz radiation.

Abstract: The present invention relates to compounds of general formula 1 for the treatment of bronchial asthma by inhibition of IL-4 or IL-5 pathway inhibition. The present invention also relates to the use of compound of general formula 1 for the treatment of bronchial by inhibition of IL-4 or IL-5 pathway. The present invention also relates to the method of treating asthma by inhibition of IL-4 or IL-5 pathway by administration of compound or said composition through oral, intranasal, route or by inhalation to a mammal in need thereof. Compound of general formula 1 may be used for reducing perivascular and peribronchial inflammation.

Abstract: This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and/or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.

Abstract: Present invention provides a pharmaceutical composition useful for the treatment of prostate cancer in a subject wherein the said composition comprising the therapeutically effective amount of an extract obtained from any plant parts of Murrya koenigii and Tribulus terrestris.

Abstract: The present invention is directed to pharmaceutical compositions and methods for treatment of prostate cancer in a subject. The pharmaceutical composition includes a therapeutically effective amount of compound mahanine, or derivatives, or analogues, or pharmaceutically acceptable salt thereof. The present invention is further directed to a method of isolating compound mahanine from Murraya koenigii.

Abstract: This invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, and a treatment of chronic myeloid leukemia (CML) by a composition comprising an effective amount of analogs and/or salts of chlorogenic acid. The analogs are preferably sodium chlorogenate (Na-Chl) or potassium or ammonium salts, which were prepared from Chlorogenic acid or its analogs.